Status:
COMPLETED
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborating Sponsors:
Pharmacia and Upjohn
Conditions:
Esophageal Cancer
Esophagus Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To determine the most efficacious of two combination regimens of sequential CPT-11 and MMC in patients with advanced and previously untreated esophageal and GE junction adenocarcinomas.
Detailed Description
Rationale: Previous studies suggest that both irinotecan and Mytomycin C when administered alone have some efficacy against stomach cancer. Based on laboratory testing, researchers hypothesized that M...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Must have pathologically confirmed \& measurable advanced esophageal or Gastroesophageal junction adenocarcinoma
- No prior chemotherapy
- Prior radiation allowed if \<=20% of bone marrow was irradiated
- Target lesions must not be in radiation field.
Exclusion
Key Trial Info
Start Date :
September 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00201747
Start Date
September 1 2001
End Date
February 1 2010
Last Update
December 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University
Columbus, Ohio, United States, 43210